These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 7634618

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mechanisms of cancer-induced hypercalcemia.
    Rosol TJ, Capen CC.
    Lab Invest; 1992 Dec; 67(6):680-702. PubMed ID: 1460860
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein.
    Wysolmerski JJ, Broadus AE.
    Annu Rev Med; 1994 Dec; 45():189-200. PubMed ID: 8198376
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
    Rosner MH, Dalkin AC.
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
    [Abstract] [Full Text] [Related]

  • 8. Hypercalcemia of malignancy--new insights into an old syndrome.
    Esbrit P.
    Clin Lab; 2001 Oct; 47(1-2):67-71. PubMed ID: 11214225
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [PTHrP and breast cancer].
    Devys A, Lortholary A, Audran M.
    Bull Cancer; 2001 Nov; 88(11):1075-80. PubMed ID: 11741801
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of malignancy-associated hypercalcemia].
    Endo I, Inoue D.
    Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I, Kousidou OCh, Karamanos NK.
    In Vivo; 2005 Apr; 19(1):311-8. PubMed ID: 15796191
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
    Coleman RE.
    Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
    [Abstract] [Full Text] [Related]

  • 16. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E.
    Clin Cancer Res; 2005 Jun 01; 11(11):4198-203. PubMed ID: 15930357
    [Abstract] [Full Text] [Related]

  • 17. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ.
    Can J Oncol; 1995 Dec 01; 5 Suppl 1():16-27. PubMed ID: 8853520
    [Abstract] [Full Text] [Related]

  • 18. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D, Plestina S, Belev B, Unusić J, Pavlinić-Diminić V.
    Lijec Vjesn; 1999 Dec 01; 121(9-10):296-301. PubMed ID: 19658372
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Value of Clodronate in the treatment of bone metastasis].
    Pouillart P, Beuzeboc P.
    Bull Cancer; 1991 Dec 01; 78(8):737-41. PubMed ID: 1834287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.